Corline Biomedical AB (CLBIO) — Cash Flow Reinvestment Rate
Corline Biomedical AB (CLBIO) has a Cash Flow Reinvestment Rate of 1.60x as of March 2024, reinvesting Skr3.67 Million (capex Skr1.83 Million plus investments Skr-1.83 Million) from operating cash flow of Skr2.30 Million. Check CLBIO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Corline Biomedical AB Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Corline Biomedical AB across 1 annual periods. Explore Corline Biomedical AB cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Corline Biomedical AB (2023–2023)
Year-by-year capital reinvestment analysis for Corline Biomedical AB. For live market cap and broader valuation context, see Corline Biomedical AB stock valuation.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 23.23x | Skr20.59 Million | Skr886.00K | Skr10.62 Million | — |